Pre-made Sevirumab benchmark antibody (Whole mAb, anti-HCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human betaherpesvirus 5] therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-989

Anti-HCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human betaherpesvirus 5] therapeutic antibody (Pre-made Sevirumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sevirumab (MSL-19) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.[1][2]

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-989-1mg 1mg 3090
GMP-Bios-INN-989-10mg 10mg Inquiry
GMP-Bios-INN-989-100mg 100mg Inquiry
GMP-Bios-INN-989-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Sevirumab Biosimilar, Whole Mab: Anti-Hcmv (Human Cytomegalovirus) Envelope Glycoprotein H (Gh) [Human Betaherpesvirus 5] therapeutic antibody
INN Name Sevirumab
TargetHCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human betaherpesvirus 5]
FormatWhole mAb
Derivationhuman
Species Reactivityhuman
CH1 IsotypeIgG1 - kappa
VD LCIgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesNovartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0